Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity turns negative
Q2 FY2026 total equity was -$10.42M, compared with $255.16M a year earlier. Over 3 fiscal years it compounded at +30.4% a year.
Context
- Total equity amounted to 1.0% of total assets at the end of Q2 FY2026, down 34.2 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -104.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 314.69M USD
- Year-over-year change
- +39.5%
- 4-year CAGR
- +27.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 314.69M | +39.5% |
| FY2024 | 2024-12-31 | 225.64M | -9.3% |
| FY2023 | 2023-12-31 | 248.67M | +75.1% |
| FY2022 | 2022-12-31 | 142.04M | +18.2% |
| FY2021 | 2021-12-31 | 120.21M | — |
Total Equity vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's Jun 2026 total equity of -$10.42M is the 7th highest of the 8 companies compared; the peer median is $191.36M.
- Its year-over-year change of -104.1% is the 7th highest of 8, against a peer median of -24.4%.
- Total equity amounts to 1.0% of total assets for MIRM, versus a peer median of 42.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.11B | -24.4% | +2.7% | 93.6% | |
| Jun 2026 | $523.72M | -24.7% | +45.1% | 42.1% | |
| Mar 2026 | $283.99M | +99.8% | +6.7% | 84.6% | |
| Mar 2026 | $191.36M | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | $116.59M | +24.6% | -41.4% | 37.0% | |
| Sep 2026 | $22.58M | -69.3% | +38.9% | 2.7% | |
| Jun 2026 | -$10.42M | -104.1% | +30.4% | 1.0% | |
| Mar 2026 | -$229M | -251.4% | — | 17.7% | |
| Peer median (excluding MIRM) | $191.36M | -24.4% | +4.7% | 42.1% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.34M | 28M | 286.33M | 222.5M | 296.68M |
| Short-term Investments | 125.2M | 123.72M | 0 | 57.81M | 86.64M |
| Net Receivables | 4.37M | 23.99M | 67.97M | 78.29M | 123.33M |
| Inventory | 1.51M | 5.57M | 22.31M | 22.4M | 24.89M |
| Other Current Assets | 4.17M | 8.95M | 10.94M | 11.78M | 18.14M |
| Total Current Assets | 166.59M | 190.23M | 387.54M | 392.79M | 549.68M |
| Property, Plant & Equipment (Net) | 2.55M | 2.35M | 1.99M | 9.81M | 10.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 18.74M | 58.95M | 252.93M | 249.82M | 260.92M |
| Long-term Investments | 4.98M | 0 | 0 | 12.53M | 8.11M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 101.79M | 101.38M | 4.17M | 5.81M | 13.5M |
| Total Non-current Assets | 128.06M | 162.68M | 259.08M | 277.97M | 293.13M |
| Total Assets | 294.65M | 352.91M | 646.62M | 670.75M | 842.81M |
| Account Payables | 9.17M | 8.69M | 7.42M | 14.62M | 9.61M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.98M | 15.75M | 20.94M | 32.25M | 47.28M |
| Total Current Liabilities | 42.6M | 64.73M | 87.06M | 126.55M | 205.8M |
| Long-term Debt | 0 | 0 | 306.42M | 308.08M | 309.8M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 129.92M | 140.35M | 0 | 0 | 0 |
| Other Non-current Liabilities | 17K | 4.53M | 3.85M | 2.51M | 5.01M |
| Total Non-current Liabilities | 131.84M | 146.14M | 310.89M | 318.56M | 322.32M |
| Total Liabilities | 174.44M | 210.87M | 397.95M | 445.11M | 528.12M |
| Common Stock | 3K | 4K | 5K | 5K | 5K |
| Retained Earnings | (257.16M) | (392.82M) | (556.24M) | (644.18M) | (667.54M) |
| Accumulated OCI | (35K) | (217K) | 1.64M | (373K) | 351K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 120.21M | 142.04M | 248.67M | 225.64M | 314.69M |
| Total Debt | 2.61M | 2.19M | 308.14M | 317.76M | 319.45M |
| Net Debt | (28.73M) | (25.82M) | 21.82M | 95.26M | 22.77M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.